Cover Page |
12 Months Ended |
|---|---|
Dec. 31, 2021 | |
| Document Information [Line Items] | |
| Document Type | POS AM |
| Entity Registrant Name | Clarus Therapeutics Holdings, Inc. |
| Amendment Flag | true |
| Document Period End Date | Dec. 31, 2021 |
| Document Fiscal Year Focus | 2021 |
| Document Fiscal Period Focus | FY |
| Entity Central Index Key | 0001817944 |
| Entity Filer Category | Non-accelerated Filer |
| Entity Small Business | true |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | On September 30, 2021, we filed a registration statement on Form S-1 (File No. 333-259915) (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”). The Registration Statement registered for resale (i) up to 19,816,610 shares of Common Stock (including up to 3,445,000 shares of Common Stock that may be issued upon exercise of warrants (the “Placement Warrants”)) and (ii) up to 3,445,000 Placement Warrants held by the selling securityholders named therein. The Registration Statement was declared effective by the SEC on October 7, 2021. This post-effective amendment is being filed to include information from our Annual Report on Form 10-K for the year ended December 31, 2021 that was filed on March 31, 2022. No additional securities are being registered under this post-effective amendment and all applicable registration and filing fees were paid at the time of the original filing of the Registration Statement. |